Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc announced on Tuesday an agreement to acquire Caraway Therapeutics Inc for a total potential consideration of up to $610 million, including an undisclosed upfront payment and earnout milestones linked to the development of certain drugs Caraway has in the pipeline.  Caraway, a drug developer, has a drug pipeline that includes experimental treatment of genetically defined neurodegenerative and rare diseases, such as Parkinson's disease.

Merck to acquire Caraway Therapeutics for up to $610M

Merck & Co. Inc. MRK said Tuesday it agreed to pay up to $610 million to acquire Caraway Therapeutics, a preclinical biopharmaceutical company pursuing new approaches for the treatment of genetically defined neurodegenerative and rare diseases. The company's pipeline includes novel, small-molecule therapeutics for the treatment of genetically defined neurodegenerative and rare diseases.

Merck paying $610 million for Caraway Therapeutics

Merck reported positive quarterly earnings with 6.7% year-over-year revenue growth and improved operating margin. The company generated strong leveraged free cash flow and reduced financial leverage, improving its net debt position. Merck has raised dividends for 12 consecutive years with an average growth rate nearing 10%.

Merck: A Dividend Growth Stock Worth Considering

Apple

Amazon

Boeing

Bank of America

Alphabet

JPMorgan Chase & Co

Marathon Petroleum

Microsoft

Micron Technology

NVIDIA

Pfizer

Tesla

Valero Energy

Wells Fargo

In a simple world, the stock market is never more than earnings and the multiple investors assign to them.

These ten stocks, not just from tech, are the key to next year's S&P 500 earnings growth

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference.

Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference

The U.S. health regulator's advisers on Friday did not recommend Merck's drug for the treatment of chronic cough.

US FDA panel votes against Merck's chronic cough drug

Broadcom

Citigroup

Cisco Systems

Dell Technologies

Simon Property Group

Exxon Mobil

2023 has been a much better year than 2022, as all major indices are higher. The tech-heavy Nasdaq is up a whopping 32.5%, while the venerable S&P 500 is up 15.36% and the Dow Jones Industrial just 3.5%, but it hasn't felt like a bull market, at least not yet.

7 Dividend Stocks To Buy For the Coming Bull Market

Following this approval, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers. Overall, the drug is approved for 38 indications in the country.

Merck (MRK) Gets FDA Nod for Keytruda Expansion in Gastric Cancer

Merck & Co Inc (NYSE:MRK) announced on Thursday that its anti-PD-1 therapy Keytruda in combination with chemotherapy has been approved by the U.S. Food and Drug Administration (FDA) for gastric cancer.  This marks the 38th indication to win approval for Keytruda regimens in the United States and the seventh gastrointestinal cancer indication, Merck highlighted.

Merck's Keytruda combo wins FDA approval for gastric cancer

Merck MRK, +0.63% said late Thursday that the Food and Drug Administration has approved its star cancer drug Keytruda as treatment for some adult gastrointestinal cancers, alongside chemotherapy. Approval was based on results from an advanced-stage trial that “demonstrated significant improvement in overall survival in these patients versus chemotherapy alone,” the drug company said.

Merck's Keytruda gets approval to treat certain types of gastric cancer

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves Merck's KEYTRUDA Plus Chemo as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or GEJ Cancer.

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference (Transcript)

U.S. Food and Drug Administration's reviewers on Wednesday flagged concerns that data on Merck's chronic cough drug might not be sufficient to prove meaningful benefit, according to documents released ahead of the agency advisers' meeting this week.

US FDA staff flags concerns on Merck's chronic cough drug

Intuitive Surgical

Merck has the tools to manage a major patent cliff that is coming in the next few years. Intuitive Surgical's leadership in its field and growth avenues make it a strong buy.

2 Healthcare Stocks That Could Make You Richer

Merck (NYSE: MRK) reported its Q3 results last month, with revenues and earnings beating the street estimates, and we believe that MRK stock has ample room for growth,

At $100 Does Merck Stock Have Room For Growth?

The stock market is rallying after a decline in Treasury yields boosted the case for company shares.

Earnings Estimates Are Falling. These Two Companies Are Shouldering the Blame.

Lockheed Martin

Walmart

Investment is not just the art of finding potential multi-bagger stocks. There is a lot of thinking and strategizing involved in creating a portfolio that beats the index, delivers regular cash flows, and ensures capital preservation in challenging market conditions.

The 3 Best Defensive Stocks for Uncertain Times

NIKE

Agilent Technologies

Automatic Data Processing

American Equity Investment Life

Assurant

Atmos Energy

Becton, Dickinson and Co.

Cencora Inc

CubeSmart

Emerson Electric

Evergy Inc

Huntington Ingalls Industries

Hormel Foods

Lancaster Colony

Matthews International

McCormick

Motorola Solutions

Nelnet

Royal Gold

Roper Technologies

Snap-on

Spire

York Water

Investors were rewarded with 10%+ dividend increases from Snap-on Tools and ADP in the first half of November. Other companies that rewarded investors in the first two weeks of the month were Emerson, which extended its dividend growth streak to 67 years, and utilities Atmos and Evergy. The second half of the month will bring dividend increases from Nike, Merck, Hormel and Agilent, among others.

Nike, Merck Among 13 Companies To Announce Annual Dividend Increases In Second Half Of November

If you're looking for companies with steady profitability, cash flow and dividends, then Broadcom Inc. NASDAQ: AVGO, McCormick & Co. Inc. NYSE: MKC and Merck & Co. NYSE: MRK are worthy candidates.

3 S&P stocks with growth to weather a downturn

Amgen

Gilead Sciences

Sanofi

While many Wall Street firms are suggesting short Treasury paper and money markets now, for long-term investors looking for growth and income, healthcare is the place to be for the rest of 2023 and likely 2024.

5 Dirt-Cheap Healthcare Stocks With Big Dividends To Buy Now

Merck & Co., Inc. (NYSE:MRK ) UBS BioPharma Conference November 8, 2023 12:00 PM ET Company Participants Jannie Oosthuizen - President, U.S. Human Health Business, Merck Conference Call Participants Trung Huynh - UBS Trung Huynh Okay. We're at the top of the hour now.

Merck & Co., Inc. (MRK) Presents at UBS BioPharma Conference (Transcript)

Bristol-Myers

Merck and Bristol Myers Squibb are developing antibody-drug conjugates. Both are acquiring biotechs and assets to beef up their pipelines.

Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?

Merck & Co Inc (NYSE:MRK) announced Friday that its drug Keytruda has been backed by the European Medicines Agency's Committee for Medicinal Products in Human Use (CHMP) for use in certain patients with biliary tract cancer. The CHMP's recommendation to approve Keytruda in combination with gemcitabine and cisplatin for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma will now be reviewed by the European Commission for marketing authorization in the European Union, with a final decision expected by the year-end.

Merck's drug Keytruda recommended for EU approval for biliary tract cancer

News for Merck Stock (MRK)